eicosapentaenoic acid ethyl ester has been researched along with Cognition Disorders in 2 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder." | 9.09 | A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. ( Boronow, J; Dickerson, F; Fenton, WS; Hibbeln, JR; Knable, M, 2001) |
| "This study determined if augmentation of neuroleptics with 3 g/day of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in patients with schizophrenia or schizoaffective disorder." | 5.09 | A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. ( Boronow, J; Dickerson, F; Fenton, WS; Hibbeln, JR; Knable, M, 2001) |
| " Pre-administration of TAK-085 (highly purified and concentrated n-3 fatty acids containing eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester) at 300 mg kg(-1) day(-1) for 12 weeks significantly reduced the number of reference memory errors in an 8-arm radial maze, suggesting that long-term administration of TAK-085 improves cognitive leaning ability in rats." | 1.37 | Protective effects of prescription n-3 fatty acids against impairment of spatial cognitive learning ability in amyloid β-infused rats. ( Gamoh, S; Haque, AM; Hashimoto, M; Katakura, M; Shahdat, H; Shido, O; Tanabe, Y; Tozawa, R, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M | 1 |
| Tozawa, R | 1 |
| Katakura, M | 1 |
| Shahdat, H | 1 |
| Haque, AM | 1 |
| Tanabe, Y | 1 |
| Gamoh, S | 1 |
| Shido, O | 1 |
| Fenton, WS | 1 |
| Dickerson, F | 1 |
| Boronow, J | 1 |
| Hibbeln, JR | 1 |
| Knable, M | 1 |
1 trial available for eicosapentaenoic acid ethyl ester and Cognition Disorders
| Article | Year |
|---|---|
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Ei | 2001 |
1 other study available for eicosapentaenoic acid ethyl ester and Cognition Disorders
| Article | Year |
|---|---|
Protective effects of prescription n-3 fatty acids against impairment of spatial cognitive learning ability in amyloid β-infused rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cerebral Ventricles; Cognition D | 2011 |